The international, prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients - PubMed
5 hours ago
- #CytoSorb
- #Blood Purification
- #Critical Care
- The COSMOS Registry evaluates CytoSorb® use in critically ill patients, tracking outcomes and safety.
- 300 patients (mean age 59, 30.3% female) from 22 sites were included, with septic shock (48.3%) as the most common indication.
- CytoSorb® was often used with kidney replacement therapy (75.6%) and showed improvements in fluid balance, norepinephrine requirements, and P/F ratio.
- Platelet counts decreased significantly post-treatment, but albumin levels remained stable.
- ICU mortality was 33.1%, lower than expected based on APACHE II and SOFA scores.
- No serious device-related adverse effects were reported.
- Findings suggest clinical benefits but require cautious interpretation due to the observational design and lack of a control group.